Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction

Critical Care Medicine

Volumn 34, Issue 5, 2006, Pages 1351-1357

  Nakanishi, Kazuhiro ^a   Takeda, Shinhiro ^a   Sakamoto, Atsuhiro ^a   Kitamura, Akira ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cardiopulmonary bypass; Neutrophil elastase; Proinflammatory cytokines; Reperfusion injury; Troponin T; Ulinastatin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE BB; CREATINE KINASE MM; DIURETIC AGENT; DOPAMINE; FENTANYL; INTERLEUKIN 6; INTERLEUKIN 8; ISOFLURANE; LEUKOCYTE ELASTASE; MIDAZOLAM; MYOSIN LIGHT CHAIN; NITRATE; NORADRENALIN; ORAL ANTIDIABETIC AGENT; PHENYLEPHRINE; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PROPOFOL; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; VECURONIUM; CYTOKINE; GLYCOPROTEIN; TRYPSIN INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HEART STROKE VOLUME; HEMATOCRIT; HEMODYNAMICS; HUMAN; INTUBATION; LUNG ARTERIOVENOUS SHUNT; LUNG DISEASE; LUNG INJURY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; UNIVERSITY HOSPITAL; ADULT RESPIRATORY DISTRESS SYNDROME; ANALYSIS OF VARIANCE; BLOOD; DRUG EFFECT; MIDDLE AGED; PROSPECTIVE STUDY;

ANALYSIS OF VARIANCE; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; GLYCOPROTEINS; HEMODYNAMIC PROCESSES; HUMANS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT; TROPONIN T; TRYPSIN INHIBITORS;

EID: 33646591214     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000215110.55899.AE     Document Type: Article

References (47)

1. Wan S, LeClerc JL, Vincent JL: Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies. Chest 1997; 112:676-692
2. Asimakopoulos G, Smith PLC, Ratnatunga CP, et al: Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999; 68:1107-1115
3. Boyle EM, Pohlman TH, Johnson MC, et al: The systemic inflammatory response. Ann Thorac Surg 1997; 64:S31-S37
4. Chaney MA, Durazo-Arvizu RA, Nikolov NP, et al: Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation. Thorac Cardiovasc Surg 2001; 121:561-569
5. Chaney MA, Nicolov MP, Blakeman BP, et al: Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Ann Thorac Surg 1999; 67:1006-1011
6. Chaney MA, Nicolov MP, Blakeman BP, et al: Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg 1998; 87:27-33
7. Hirose J, Ozawa T, Miura T, et al: Human neutrophil elastase degrades inter-α-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998; 21:651-656
8. Endo S, Inada K, Yamashita H, et al: The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res Commun Chem Pathol Pharmacol 1993; 82:27-34
9. Nakatani K, Takeshita S, Tsujimoto H, et al: Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001; 69:241-247
10. Aihara T, Shiraishi M, Hiroyasu S, et al: Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by down-regulating TNF-α in the liver. Transplant Proc 1998; 30:3732-3734
11. Nakahama H, Obata K, Sugita M: Ulinastatin ameliorates acute ischemic renal injury in rats. Renal Failure 1996; 18:893-898
12. Cao ZL, Okazaki Y, Naito K, et al: Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart. Ann Thorac Surg 2000; 69:1121-1126
13. Binns OAR, Dekima NF, Buchanan SA, et al: Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 1996; 112:607-613
14. Kanayama N, Halim A, Maehara K, et al: Kunitz-type trypsin inhibitor prevents LPS-induced increase of cytosolic free Ca2+ in human neutrophils and HUVEC cells. Biochem Biophys Res Commun 1995; 207: 324-330
15. Endo S, Inada K, Taki K, et al: Inhibitory effects of ulinastatin on the production of cytokines: Implications for the prevention of septicemic shock. Clin Ther 1990; 12:323-326
16. Maehara K, Kanayama N, Halim A, et al: Down-regulation of interleukin-8 gene expression in HL60 cell line by human Kunitz-type trypsin inhibitor. Biochem Biophys Res Commun 1995; 206:926-934
17. Tsujino T, Komatsu Y, Isayama H, et al: Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3:376-383
18. Sugiura Y, Nakajima K, Kawase H, et al: Evaluation of a large dose intravenous administration of ulinastatin. Jpn J Acute Med 1988; 14:1153-1156
19. Nishiyama T, Hanaoka K: Do the effects of a protease inhibitor, ulinastatin, on elastase release by blood transfusion depend on interleukin 6? Crit Care Med 2001; 29:2106-2110
20. Buckberg GD: Antegrade/retrograde blood cardioplegia to ensure cardioplegic distribution: Operative techniques and objectives. J Card Surg 1989; 4:216-238
21. Taylor KM, Bain WH, Jones JV, et al: The effect of hemodilution on plasma levels of cortisol and free cortisol. J Thorac Cardiovasc Surg 1976; 72:57-61
22. Wan S, DeSmet JM, Barvais L, et al: Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 112:806-811
23. Brasil LA, Gomes WJ, Salomao R, et al: Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 1998; 66:56-59
24. Haeffner-Cavaillon N, Roussellier N, Ponzio O, et al: Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 98:1100-1106
25. Honore PM, Jacquet LM, Beale RJ, et al: Effects of normothermia versus hypothermia on extravascular lung water and serum cytokines during cardiopulmonary bypass: A randomized, controlled trial. Crit Care Med 2001; 29:1903-1909
26. Strieter RM, Kunkel SL, Showell HJ, et al: Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS and IL-1β. Science (United States) 1989; 243:1467-1469
27. Matsushima K, Morishita K, Yoshimura T, et al: Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 1988; 167:1883-1893
28. Mukaida N, Mahe Y, Matsushima K: Cooperative interaction of nuclear factor-κB and cis-regulatory enhancer binding protein-like factor binding elements inactivating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 1990; 165:21128-21133
29. Sekido N, Mukaida N, Harada A, et al: Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature (England) 1993; 365:654-657
30. Beutter B, Cerami A: The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 1989; 7:625-655
31. Andersen LW, Landow L, Baek L, et al: Association between gastric mucosal pH and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor-alpha concentrations in patients undergoing cardiopulmonary bypass. Crit Care Med 1993; 231:210-217
32. Pallua N, Low JF, von Heimburg D: Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of antiinterleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. Crit Care Med 2003; 31:1495-1501
33. Shalaby MR, Waage A, Aarden L, et al: Endotoxin and tumor necrosis factor-α and interleukin-1 induce interleukin-6 production in vivo. Clin Immunol Immunopathol 1989; 53:488-498
34. Onai H, Kudo: Suppression of superantigen-induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor. Eur J Clin Invest 2001; 31:272-280
35. Faymonville ME, Pincemail J, Duchateau J, et al: Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991; 102:309-317
36. Rao SK, Mathrubutham M, Sherman D, et al: A versatile microassay for elastase using succinylated elastin. Anal Biochem 1977; 250:222-227
37. Tonz M, Mihaljevic T, von Segesser LK, et al: Acute lung injury during cardiopulmonary bypass. Are the neutrophils responsible? Chest 1995; 108:1551-1556
38. Zimmerman BJ, Granger DN: Reperfusion-induced leukocyte infiltration: Role of elastase. Am J Physiol 1990; 259:H390-H394
39. Reid PT, Sallenave JM: Neutrophil-derived elastases and their inhibitors: Potential role in the pathogenesis of lung disease. Curr Opin Investig Drugs 2001; 2:59-67
40. Frass OM, Bühling F, Täger M, et al: Antioxidant and antiprotease status in peripheral blood and BAL fluid after cardiopulmonary bypass. Chest 2001; 120:1599-1608
41. Hennein HA, Ebba H, Rodriguez JL, et al: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108:626-635
42. Finkel MS, Hoffman RA, Shen L, et al: Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol 1993; 71:1231-1232
43. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effect of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
44. Kukielka GL, Smith CW, LaRosa GJ, et al: Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995; 95:89-103
45. Wan S, LeClerc JL, Vincent JL: Cytokine responses to cardiopulmonary bypass: Lessons learned from cardiac transplantation. Ann Thorac Surg 1997; 63:269-276
46. Wan S, Izzat MB, Lee TW, et al: Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg 1999; 68:52-57
47. Jonsson-Berling BM, Ohlsson K: Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scand J Clin Lab Invest 1991; 51:549-557